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LITERATURE REVIEW 
Cell mediated immunity is a key component in the bodys defense against viral and 
bacterial invaders as well as tumor cells. Various cellular effectors provide essential 
functions, such as lysis of bacterial or virally infected cells with concomitant production of 
various anti-bacterial or anti-viral cytokines, and by mediating tumor cell lysis; thereby 
protecting the body against the spread of infection and the formation of tumors. Cell 
mediated immunity involves various lymphocyte subsets including cytotoxic T lymphocytes, 
helper T lymphocytes, and large granular lymphocytes (i .e. natural killer cells). Natural 
killer (NK) cells were the first type of cell found to be capable of lysis of tumor and virally 
infected cell independent of prior antigen presentation (i.e. NK activity) . Additionally, low 
NK cell function has been linked to increased incidence of tumor formation. For these 
reasons, much research has focused on NK cells and other cells capable of NK-like activity. 
Natural Killer Cells 
Natural killer cells were discovered about 15 years ago during the investigation of cell-
mediated cytotoxicity (Herberman et al., 1975; Kiessling et al., 1975a; Kiessling et al., 
1976). Investigators were surprised to find that lymphocytes from a normal, healthy 
individual possessed appreciable cytotoxic activity against a variety of tumor cells, some 
microorganisms, and against virally infected cells. These lymphocytes, were called natural 
killer cells due to the spontaneous cytotoxicity exhibited against various target cells. Natural 
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killer cells represent a subset of lymphocytes (approx. 5 % ); they differ from T and B 
lymphocytes by their morphology, cell surface phenotype, and functional ability to 
spontaneously kill a variety of tumor cells and virally infected cells independent of major 
histocompatibility complex (MHC) restriction (Jondal et al., 1987; Ortaldo et al. , 1987) or 
prior sensitization by antigens (Henney et al., 1978; Herberman and Ortaldo 1981; Karre 
et al., 1980). The unique property of NK cells being functionally un-restricted by the MHC 
which gives them the capacity to kill cells with no detectable MHC antigen, such as occurs 
with a variety of human solid tumor, leukemic, or virally-infected cells. Additionally, if 
recognition and binding of processed antigen in the presence of MHC were required, the 
time allowed for a specific immune response to be initiated could let tumor cells or viruses 
replicate out of control of such a response. Therefore, the lack of requirement for MHC 
restriction enables these cells to play a primary role in immune surveillance against tumors 
and infectious agents. 
Morphologically, NK cells are a subpopulation of lymphocytes, large granular 
lymphocytes (LGLs), that constitute about 5 % of peripheral blood lymphocytes and 1-3 % 
of total mononuclear cells (fimonen and Sakesela, 1980; Timonen et al., 1981, 1982a, b; 
Reynolds et al., 1981a and b; Reynolds et al . , 1982; Kumugai et al . , 1982) . Additionally, 
LGLs are non-phagocytic, non-adherent cells that lack surface immunoglobulin and T cell 
receptor molecules. 
Most LGLs have surface receptors for the Fe portion of IgG, and thereby mediate both 
antibody-dependent cellular cytotoxicity (ADCC) and NK activity (Herberman 1980; 
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Herberman 1982; Herberman and Ortaldo, 1981). NK cells can mediate either Fc-R 
dependent cytotoxicity (ADCC) against antibody-coated target cells or direct cytotoxicity 
against a variety of tumor cells. Cross-linkage of NK cell FcRIII (CD 16) with anti-FcRITI 
(anti-CD16) mAb or direct binding to NK-sensitive tumor targets results in a phospholipase-
C mediated release of inositol phosphates, activation of protein kinases and increases in 
intracellular [Ca2+], which are critical early components of this signal transduction processes 
in NK cells (Seaman et al., 1987; Windebank et al., 1988; Steele and Brahmi, 1988; Chow 
et al., 1988; Cassatella et al. , 1989; Edwards et al., 1989). This receptor dependent [Ca2+] 
increase consists of primary calcium release from intracellular stores, and a secondary influx 
of calcium across the plasma membrane (Leib son et al., 1990). This mobilization of 
intracellular calcium and subsequent protein kinase-C (PKC) activation is a result of 
phospholipase C-catalyzed hydrolysis of phosphoinositides which leads to the production of 
second messengers (Berridge and Irvine, 1989). In fact, pharmacologic reagents that directly 
increase intracellular calcium and PKC activation (i .e. calcium ionphores and phorbol esters, 
respectively) directly initiate NK cell activation without exposure to cellular targets (Goldfarb 
and Herberman, 1981; Seaman et al., 1981 ; Abrams et al., 1983; Beckner and Farrar, 1988; 
Cuturi and Murphy, 1987; Ortaldo et al., 1989; Nishimura et al ., 1989). These intracellular 
events ultimately affect changes in specific gene expression, cellular proliferation, cytokine 
secretion, and cell-mediated cytotoxicity. The mechanism of tumor target cell recognition 
and spontaneous cytotoxicity in NK cells is still unclear. However, tumor cell lysis is known 
to require Mg2+ ions, can occur at 4°C as well as 37°C and is not inhibited by azide, while 
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Mg2+, low temperatures and azide all inhibit Tc cell adhesion to targets (Targan and 
Newman, 1983). Upon recognition, a number of organelles become localized directly 
between the nucleus of the effector cell and the region of plasma membrane in contact with 
the target cell. This reorientation of organelles facilitates the movement of cytoplasmic 
granules and/or secretory vesicles towards the target cell, with the eventual release of their 
toxic contents via a Ca2 + dependent exocytosis (Austyn and Wood, 1994). Soon after the 
cytoplasm is reorganized the granules, containing perforin and various proteolytic enzymes 
(specifically, serine proteinases termed granzymes), are released and the target cell dies 
(Smyth and Trapani, 1995). Perforin polymerizes into transmembrane channels, intercalates 
into the target cell membrane, and produce pores like those produced by the complement 
membrane attack complex (MAC) . This pore formation alone is capable of lysing some 
target cells due to osmotic lysis . Internal disintegration of target cells occurs due to 
granzymes (and possibly other components) penetrating the newly formed pores and 
triggering pathways leading to apoptosis (programmed cell death) within a few minutes of 
encountering an appropriate target cell (Smyth and Trapani, 1995). This process is thought 
to be similar to cytotoxic T cell activity , except for the mechanism of target cell recognition 
which, characteristically, is mediated by T-cell Receptor molecules (TCR) and a specific 
peptide-MHC complex. Additionally, Tc cell killing usually only develops after an immune 
response to the target has been initiated, except under special circumstances to be discussed 
later. In addition to the pore forming route, NK and CTLs are also capable of target cell 
lysis mediated through a non-pore forming route facilitated through ligation of the Fas 
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protein on the target cell by Fas ligand on the effector cell, but the exact pathway remains 
unclear (Smyth and Trapani, 1995). 
Phenotypically, several cell surface antigens have been identified on the surface of NK 
cells through the use of monoclonal antibodies. Many of these antigens can be found on 
other blood lymphocytes such as monocytes and various T-cells but NK cells express a 
characteristic array of surface markers. Generally, NK cells are cn3- (pan-T-cell marker), 
CD56+(NKH1 +), CD16+(Fc receptor for IgG-also found on granulocytes (PMN)), which 
is a highly lytic cell type. This is in contrast to CD3-, CD56+ and CD16- which is an NK 
cell subset with lower lytic activity (Hatam et al., 1993). More recently, NK cells have 
been found to be positive for the CD8alpha chain (Mab OX-8), when both the a and {3 chain 
are found together on cytotoxic T-cells. Several new monoclonal antibodies specific for cell 
surface molecules specific for NK cells have been developed. For example, NKR-Pl a 24.5 
kD transmembrane glycoprotein found on the surface of rat NK cells, LGL's and 
polymorphonuclear cells. This molecule has also been implicated in signal transduction (Ryan 
et al., 1991; Giorda et al. , 1990). 
NK cells appear to play a key role in immune surveillance against tumors and represent 
a primary defense against the metastatic spread of blood-borne tumor cells. In animal 
models the intravenous injection of tumor cells and subsequent development of metastasis is 
dramatically increased when NK cell populations are decreased; resistance is restored upon 
reconstitution of the NK cell population (Barlozzari et al., 1983; Pollack and Hollenbeck, 
1982). Patients with disseminated cancer, including breast carcinomas or melanomas, have 
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significantly lower NK function, measured as spontaneous cytotoxicity to tumor targets, than 
those whose disease remained localized. Several clinical studies have revealed an inverse 
relationship between spontaneous cytotoxicity and both localized and metastatic disease 
(Cunningham-Rundles et al., 1981; Pross and Baines, 1976; Steinhauer et al., 1982; 
Takasugi et al., 1977; Trinchieri and Perussia, 1984). Additionally, the survival time 
without metastasis in patients treated for metastatic disease correlates well with the levels 
of spontaneous cytotoxicity (Choe et al., 1987; Hirofuji et al. , 1987; Schantz et al., 1987; 
Son et al., 1982). 
In the case of leukemias in relapse, spontaneous cytotoxicity was found to be lower than 
the activity found in patients who were in complete remission or normal donors (Adler et al., 
1988; Matera and Giancotti , 1983). Reasons for this could be reduced numbers of 
circulating effector cells , defective function, and/or the presence of suppressor factors . 
The vital function of NK cells , as a defense against cancer, alludes to the severity of 
disease states that may be caused by a dysfunction or lack of natural killer cells. Patients 
with Chediak-Higashi syndrome have a high incidence of lymphoproliferative diseases due 
to a selective and pronounced deficit in spontaneous cytotoxicity (Haliotis et al ., 1980; 
Roder et al. , 1980). Moreover, high dose immunosuppressive therapy given to transplant 
patients to prevent graft rejection, depletes NK cells thereby making these patients at high 
risk for lymphoproliferative disease and other malignancies (Frizzera et al., 1981 ; Starzl et 
al., 1985). These studies of lymphoproliferative disease confirm the possibility that the NK 
cell system plays a major role in immunosurveillance in the prevention of cancer. 
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Recently, several types of cells have also been shown to have the ability to exhibit MHC 
unrestricted killing or natural killer-like activity , where in the past this activity was attributed 
to NK cells because the most commonly used assay (5 1Cr release assay, see materials and 
methods) to detect spontaneous cytotoxicity cannot differentiate between the cell types 
responsible for the spontaneous cytotoxicity. Scientists are now able to differentiate the 
lymphocytes capable of spontaneous cytotoxicity through the use of monoclonal antibodies 
and flow cytometric analysis . Even though some cells involved in the regulation of 
spontaneous cytotoxicity do comprise a distinct lineage, there can be no question that cells 
comprising other lineages may acquire such spontaneous cytotoxicity or NK-like activity at 
one stage or another of their development or activation. 
Several types of T cells are capable of MHC-unrestricted cytotoxicity, although certain 
populations appear to posses an increased ability for spontaneous killing. In particular 
cytotoxic T-lymphocytes (CTL), which are normally MHC-restricted, can also generate the 
ability to kill cells that are referred to as targets for NK cells in an MHC-unrestricted 
manner, particularly after they have been cultured in the presence of interleukin-2 (IL-2) 
(Acha-Orbea et al., 1983). It is feasible to reason that spontaneous cytotoxicity could be a 
function of cells other than NK cells in vivo, such as IL-2 induced CTL. Additionally, 
Matthew and colleagues (1993) have characterized a molecule believed to be associated with 
non-MHC-restricted killing mediated by both activated natural killer cells and T cells. 
Recently , much of the investigation of spontaneous cytotoxicity has centered on T cells 
possessing the "ftJ form of the TCR ('Y5 T-cells) . This subpopulation of T cells is capable 
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of MHC-unrestricted killing which can be augmented in the presence of various cytokines 
including IL-2, Interferon (IFN) and tumor necrosis factor-alpha (TNF-a) (Cesano et al., 
1993). In vitro, human -yo T-cells have been shown to proliferate in response to typical NK 
cell targets, which leads to cell lysis that is rarely MHC-restricted (Bukowski et al., 1994; 
Kozbor et al., 1988; Fisch et al., 1992; Okumura et al . , 1995). Additionally, Choudhary 
and colleagues (1995) observed that polyclonal tumor infiltrating lymphocytes (TIL) taken 
from renal carcinomas develop the ability for nonspecific lysis. Lymphocytes possessing 
the -yo TCR were found to be overrepresented in these populations, thereby indicating a 
potential role in tumor surveillance in vivo. 
Many immunocyte cell lines propagated in vitro are often capable of killing tumor cells 
that they are not thought to be capable of killing in vivo. For example, T-cell clones that 
have been grown in the presence of interleukin-2 IL-2 have been termed anomalous killer 
(AK) cells. It is unclear if these cells are -yo T-cells. Lymphocytes that have been cultured 
in the presence of IL-2 and have acquired cytotoxic activity in vitro have been termed 
lymphokine activated killer (LAK) cells (Phillips and Lanier, 1986). The LAK cell 
phenomenon was first associated with the ability of peripheral blood mononuclear cells 
(PBMC) which were stimulated by IL-2 to kill primary tumors and tumor cell lines resistant 
to NK cytotoxicity (Grimm et al. , 1982). Later, it was reported that, in fact, NK cells were 
the predominant IL-2-induced LAK precursor in PBMC (Trinchieri et al., 1984). 
Lymphokine activated killer cells demonstrate enhanced nonspecific lysis of tumor cells, and 
because of this are being used frequently in adoptive immunotherapy trials by removing 
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lymphocytes from the patient, expanding and activating them in the presence of IL-2, and 
transfusing the activated cells back into the patient. This treatment is generally accompanied 
by a systemic administration of high doses of IL-2. 
In addition to lymphocytes, a main feature of activated macrophages is, by definition, an 
increased lysis of tumor cells in vitro. The mechanism of this preference for tumor cells is 
unknown. Additionally, macrophages, like NK cells, have Fe receptors on their surface 
enabling them to kill tumor cells coated with antibody via ADCC. Tumor killing by 
macrophages in vitro usually requires 18-22 hours and kills a different array of cells than NK 
cells. This contrasts with NK cells which kill in 4-6 hours. In addition, some precursors of 
mononuclear phagocytes may also be able to kill in an MHC-unrestricted manner. 
Because there is ambiguity concerning the identity of NK cells, the cell surface phenotype 
of CD3-, CD56+, CD16+'- must be used to distinguish NK cells from other cells that have 
cytolytic activity even in the absence of target MHC class I and class II molecules. Due to 
the inconsistencies concerning true NK activity and NK-like activity, anytime flow cytometry 
has been performed it will be phenotypically designated throughout the rest of the text. 
Upon discovery that NK and NK-like activity (spontaneous cytotoxicity) can be 
stimulated or enhanced in a variety of cells by treatment of the cells with cytokines, such as 
IL-2, there has been much research in the area of NK cell function and regulation and the 
effect of cytokines on such function and regulation. Now that a portion of this spontaneous 
cytotoxic activity has been attributed to other cell types; researchers are beginning to identify 
ways to get maximal stimulation of tumor cytotoxicity through the use of cytokine therapy. 
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Activators of Cytolytic Activity 
Cytokines are proteins that serve as intracellular messengers like hormones although their 
function is usual! y autocrine or paracrine in nature whereas hormones are endocrine in 
nature. These regulatory peptides can be produced by nearly all nucleated cells in the body 
and induce a wide range of regulatory effects, ranging from maintaining bodily homeostasis, 
enhanced host responses to invading organisms, tumors or trauma (Austyn and Wood, 1994). 
More recently, it has been discovered that various cytokines can control, and more notably, 
increase NK cell function and replication that is stimulated during infection, inflammation, 
or other immune challenges (Cortesina et al. , 1988; Grimm et al., 1982; Henney et al. , 
1981). Recent research has focused on cytokines and other compounds that up-regulate 
immune function (known as biological response modifiers) thereby stimulating spontaneous 
cytotoxicity. The use of cytokine therapy is being studied in a wide variety of disease states 
such as autoimmune disorders, neoplasias and immunocompromised patients with AIDS. 
Resting peripheral blood NK cells can respond directly to recombinant cytokines. A key 
cytokine in regulation of NK activity is IL-2 and its effects have been studied extensively. 
Henny et al. (1981) provided the first evidence for a direct stimulatory role of IL-2 in NK 
cell function in a murine model. Since that time, treatment with IL-2 alone has been shown 
to stimulate growth and increase the activity of NK cells, increase the cytotoxic granule 
content of NK cells and T cells including CTL and -yfJ T-cells (Cesano et al., 1993), enhance 
adhesion molecule expression , and induce LAK activity and proliferative activity in human 
NK cells (Phillips et al., 1986; Trinchieri et al . , 1984; Smyth and Trapani , 1994). 
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Additionally, IL-2 has also been shown to increase ADCC activity, and induce mRNA 
transcription and secretion of cytokines in NK cells and LAK cells (Cuturi et al., 1987; 
Cuturi et al., 1989; Kasid et al. , 1988; Robertson et al ., 1992; Smyth et al., 1991) . IL-2 also 
stimulates synthesis of other T cell-derived cytokines, such as IFN-y and TNF-{3 , found to 
be key mediators of cytolytic activity in NK cells , -yb T-cells and macrophage activation . 
The systemic administration of IL-2 alone resulted in the partial or complete destruction 
of tumor mass in some patients with solid tumors, particularly melanoma and renal cell 
carcinoma (Rosenberg et al . , 1987; West et al ., 1987). Additionally, local (perilesional) 
administration of IL-2 can produce partial and complete regressions of tumors in the head 
and neck in humans (Cortesina et al . , 1988). Cancer therapy in humans utilizing 
autologous, IL-2 expanded , lymphokine-activated killer cells in combination with rIL-2, 
demonstrated increased antitumor effector function in vivo (Phillips, J. H . , 1987) . This 
combined treatment of LAK and IL-2 has been reported to yield increased frequency of 
complete regression than treatment with just IL-2 alone in several types of cancer (Phillips 
et al, 1987; Cortesina et al ., 1988; Austyn and Wood, 1994). 
Natural killer cell function can be rapidly activated in vivo by IL-2 as demonstrated by 
augmented cytotoxic activity, increased expression of activation antigens, cellular 
proliferation (Trinchieri and Perussia, 1984) and lymphokine production (Henney et al., 
1981; Anegon et al. , 1988). The process by which this activation occurs has not been 
completely elucidated . Generally , upon binding of IL-2, a target cell, or the Fe receptor, 
a rapid increase in tyrosine phosphorylation of multiple proteins in NK cells occurs in 
12 
concert with calcium influx (Einspahr et al., 1990; Einspahr et al ., 1991; Ferris et al., 1989; 
Sharon et al., 1989; Khattri et al, 1994). The majority of NK cells enter the cell cycle after 
exposure to rIL-2, in contrast to resting peripheral blood T cells which require additional 
signals such as IL-1 or activators of protein kinase C to induce proliferation (London et al., 
1986). Binding of IL-2 to either the intermediate or high affinity receptor (Kd - I nM, Kd -
10 nM respectively) induces signal transduction and cellular activation in NK cells and T-
cells (Waldman 1991; Farrar et al., 1990; Hata.keyama et al., 1989). 
Although IL-2 is a potent stimulator of spontaneous cytotoxicity, many cytokines exhibit 
a synergistic effect when administered along with IL-2. A combination of IL-2 (rlL-2) , and 
interferons-a, -{3 , or --y have been most widely used in clinical trials for treatment of cancer. 
Among various biological effects these cytokines, singly or in combination, have the 
consistent ability to increase spontaneous cytotoxicity in cancer patients as well as healthy 
individuals (Trinchieri et al., 1984). In vitro studies show that activated NK cells are 
responsible for the antitumor cytotoxicity of cultured human peripheral blood mononuclear 
cells when these cytokines are used in combination or individually (Herberman et al., 1987; 
Ortaldo et al., 1986). Activation induced by such combinations of cytokines occurs without 
a requirement for accessory cells or cofactors , and enhanced cytotoxicity can be measured 
within 4 hours post-lymphokine exposure, but is maximal at 18 hours (Trinchieri et al., 
1984; Lanier et al. , 1985). 
Interferons (IFNs) were originally named to indicate their property of 'viral interference' 
meaning that IFNs induce an anti-viral state in target cells rather than interacting with the 
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virus itself. Since virus infection was known to induce IFN, it was hypothesized that the 
boosting of NK activity was due to the induction of IFN--y following virus infection (Welsh, 
R. M., 1978). In fact, increased NK activity following virus infection or tumor response 
was found to be similar to that found following administration of IFN or IFN inducers in 
vivo. Trinchieri and co-workers (1977) first reported that human lymphocytes may be 
stimulated by some tumor cell lines to produce IFN, and although IFN can augment NK cell 
activity, this cytokine is not necessary for normal NK cell function in vitro (Trinchieri et al., 
1978; Welsh et al., 1980; Fitzgerald et al. , 1982; Minato et al ., 1980; Casali et al., 1981; 
Copeland, et al., 1981). However, IFN made in response to a virus infection in vivo, does 
lead to an increased recruitment and activation of NK cells, thereby activating cells where 
they are needed most. Interferons are now known to inhibit the growth and proliferation of 
some tumors and normal cells, and to modulate immune responses by the control of cellular 
function. Interferons also inhibit replication via phosphorylation of a number of intracellular 
proteins required for protein synthesis, and activation of endogenous endonucleases that 
become actively engaged during an infection or tumor cell growth (Austyn and Wood, 1994). 
Three different types of interferons are involved in the pleiotropy of antiviral and 
antitumor activities. Interferon-a and IFN-{3, which are produced by macrophages and 
lymphocytes (including NK cells) have a more systemic effect participating in the first line 
defense before acquired immune mechanisms come into play (Thompson, 1991), IFN--y 
induces an anti-viral state and is able to act directly on lymphocytes to promote 
differentiation and maturation of CTL (Abbas et al. , 1993). Synthesis of IFN--y is directly 
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initiated as a consequence of antigen activation, enhanced by IL-2, and produced by both by 
IL-2 secreting CD4+ helper T cells and nearly all CD8+ T cells (Abbas et al., 1993). 
Although NK cells are a minor source of interferon, NK responses to tumor cells and virus-
infected targets is often accompanied by the production of some IFN (Austyn and Wood, 
1994). 
More specifically, IFK--y may increase the number of NK cells binding to their targets 
and the rate of lysis by these cells, as well as the ability of NK cells to recycle and destroy 
more cells (Austyn and Wood, 1994). Moreover, IFN-gamma also enables non-cancer cells 
to become resistant to the increased lytic activity it grants NK cells, thereby protecting 
'normal' cells (Austyn and Wood, 1994). T-cell secreted IFN-y is also a potent macrophage 
activating agent (Andrew et al . , 1984; Kleinerman et al . , 1984). Activated macrophages can 
release reactive oxygen intermediates that allow macrophages to kill phagocytosed microbes 
and tumor cells and produce other cytotoxic molecules such as tumor necrosis factor-alpha 
(Urban et al., 1986). Interferon--y acts synergistically with other cytokines such as TNF 
enhancing the ability of macrophages to kill tumor cells (Abbas et al., 1993). 
All IFN' s have been shown to enhance NK activity and NK-like activity in PBL/PBMC 
and can partially (IFN--y) or totally (IFN-a) induce LAK activity in purified NK cells (CD 
56+ CD16+ respond better than CD56+ CDI6·). Although LAK induction by IFN--y can be 
totally independent ofIL-2 (Trinchieri et al., 1984; Ellis et al., 1989), there is a synergistic 
effect between IL-2 and IFN--y in NK cells and T cells resulting in maturation proliferation 
and/or activation (Cesano et al., 1993). Additionally, if cells are cultured in the presence 
15 
of IFN-a or IFN-')' are co-incubated with IL-2, enhancement of the IL-2 induced cytotoxicity 
is seen (Brunda et al., 1986; Tokuda et al., 1989). 
Different cell types can vary greatly in their sensitivity to effects of IFNs, although tumor 
cells may generally be more sensitive than normal cells. The growth inhibitory activity of 
IFK-a and -{3 and the stimulation of lytic activity by JFK-')' suggests that IFNs may be 
potential tumor suppressors; currently studies are being performed using intraperitoneal 
administration of IFN-')' for treatment of ovarian cancer (Austyn and Wood, 1994). 
Much research has focused on extracellular messengers or cytokines as activators of 
cytotoxic activity but some studies have shown that intracellular messengers may also be 
potent activators of spontaneous cytotoxicity. Phospholipid-dependent protein kinase C (PK-
C) has been demonstrated to play a crucial role in post receptor-binding signal transduction 
in several cell systems (Nishizuka, 1986). Recently, it has been demonstrated that the 
synergistic action of ca2+ ionophores and TPA, an activator of PK-C, can induce 
proliferation and IL-2 production by human LGL which sugggests that protein kinase-C can 
play an important role in NK cell activation and function. Additionally, selective inhibition 
of PK-C strongly inhibits spontaneous cytotoxic activity of human LGL (Procopio et al., 
1988). 
In addition to PK-C, a receptor for C reactive protein (CRP) has been identified on the 
surface of human LGL. C reactive protein is an acute phase protein, activates complement, 
acts as an opsonin , and activates macrophages and neutrophils. C reactive protein is 
involved in NK cell function since antibody against CRP inhibits NK cell lysis of K562 
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(Baum et al., 1983) and MOLT-4 (Baum et al. , 1987) human and mouse tumor cell lines, 
respectively. Anti-CRP does not block effector cell/ target cell conjugate formation and, 
therefore, is not involved in effector-target cell recognition (Baum et al. , 1987). However, 
anti-CRP does inhibit the calcium-dependent phase of signal transduction thereby blocking 
proximal events leading to cytoskeletal repolarization and the directed release of cytotoxic 
factors from activated NK cells and probably other cells that kill by degranulation (Hamoudi 
et al. , 1991; and Khattri et al., 1994). 
Lipopolysaccharides (LPS) have also been shown to rapidly enhance cytotoxicity of NK 
cells against tumor targets (Lindemann et al . , 1988a; Lindemann 1989a; Tarkkanen 1986). 
Whereas IL-2 stimulation induces long term NK cytotoxicity and proliferation (Lindemann 
et al. , 1988b), activation via bacterial products , especially LPS, is short-term with peak 
cytotoxicity occurring approximately 24 h after culture initiation (Lindemann 1989b). This 
cytotoxic induction appears to be dependent on release of interferon (IFN) by NK cells 
(Lindemann 1989b), however, significant concomitant release of IL-2 was not measured 
(Lindemann, 1988b). 
Bitter Melon 
Many compounds other than cytokines have been found to have immunostimulatory 
activity. The resurgence of herbal medicine has prompted examination of ancient folk 
remedies, such as the Chinese bitter melon, for their immunomodulatory properties. 
Momordica charantia, the bitter melon, is a member of the Cucurbitaceae family and has 
been used for over 500 years as a folk remedy in China. Recent research has shown that 
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an aqueous extract of the bitter melon has antiviral (Lee-Huang et al., 1990), antitumor/anti-
leukemic (Cunnick et al., 1990; Takemoto et al. , 1982; Jilka et al., 1983), anti-AIDS (Ng 
et al., 1992) and immune enhancing properties (Cunnick et al., 1990). The proteins 
responsible for the antiviral activity appear to be two 30 kDa glycoproteins, alpha- and beta-
momorcharin, that belong to a family of ribosome inactivating proteins (RIPs) capable of 
inhibiting ribosome function in euk.aryotic cells (Ng et al. , 1992). Ribosome inactivating 
proteins posses both cytostatic and non-specific anti-viral activity through the inhibition of 
RNA and protein synthesis. Several other plants have been found to have proteins with such 
anti-viral activity, such as trichoxanthin from Tricosanthes kirolowii and the ricin A chain 
from the castor bean. Additional! y, these proteins have been found to have some sequence 
homology with the RIP from Momordica charantia (Lee-Huang et al., 1990) . 
The anti-tumor properties of the bitter melon appears to be related to both RIP activity 
and immune enhancing properties. Pretreatment of tumor cells in vitro with crude bitter 
melon extract has been successful in reducing tumor incidence and extending the life span 
of DBA/2 mice injected with L1210 tumor cells (Cunnick et al., 1990). Additionally, mice 
which received tumor cells pretreated with bitter melon extract and intraperitoneal (ip) 
injections of the bitter melon proteins (BMP) survived the longest. Researchers concluded 
the anti-tumor component of the BMP was protein in nature because it is degraded by heat 
and proteinases and is not degraded by DNAase (Takemoto et al., 1982). 
A portion of the anti-leukemic and anti-viral 3:Ction of the bitter melon appears to be 
associated with an activation of murine lymphocytes. A partially purified protein extract 
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from . the bitter melon caused an infiltration and activation of peritoneal exudate cells in 
C57BL/6J, C3H/HeJ, and C3H/ Hen mice. Bi-weekly injections of 8 micrograms of protein , 
ip, for up to 4 weeks enhanced cytotoxicity in a long-term (18hr) and short-term (4hr) 51 Cr 
release assay against a variety of tumor targets (Cunnick et al., 1990). Antibody depletion 
studies using asialo-GMl , was able to reduce a major portion of the anti-tumor activity of 
peritoneal exudate cells in mice. It was suggested that at least part of the anti-leukemic 
activity of the bitter melon extract is due to the activation of NK cells (Cunnick et al., 1990). 
However, asialo-GM 1 is now known to be found on both CTL and NK cells (Austyn and 
Wood, 1994). 
In light of the immunostimulatory properties, some AIDS patients have used a crude 
extract of the bitter melon as a homeopathic or supplementary treatment. Preliminary results 
indicate that HIV infected individuals who have used extract of BMP have an increased life 
span but the study included few individuals and was not well controlled (Zang, 1992). Bitter 
melon treated AIDS patients demonstrated an increase in the CD4 + (i.e. , T-helper cell) 
population (Zang, 1992) . Additionally, a new inhibitor of HIV replication has been isolated 
from the seeds and fruits of the bitter melon. Momordica anti-HIV protein, (MAP 30), is 
also about 30 kDa, and exhibits dose-dependent inhibition of cell- free HIV-1 infection and 
subsequent replication. No cytotoxic or cytostatic effects were noted under experimental 
conditions indicating that MAP 30 may be a useful therapeutic agent in the treatment of HIV-
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l (Lee-Huang et al., 1990). 
The use of natural immunomodulators, such as the bitter melon, to stimulate immune 
function is very appealing to patients in light of adverse side effects often caused by drug 
treatment or the systemic administration of IL-2 that is now common practice in cancer 
treatment. In fact, food derived immunomodulators could also be used as a prophylactic, 
to keep immune function high at times when it might be suppressed such as during stressful 
life events. 
Stress and Immune Function 
Several researchers have found that stressors are able to alter the immune system in 
humans as well as animals (Cunnick et al ., 1991; Keller et al., 1988; Hillhouse et al, 1991) 
thereby increasing the susceptibility to disease in humans. The effects of stress on the 
severity or frequency of disease can be seen in studies involving rheumatoid arthritis, 
diabetes, cancer , and repeated viral infections (Fitzpatrick et al., 1988; Eaton et al., 1979; 
Jemmott, et al ., 1984; Baker et al., 1981). Additionally, stress has been identified as a co-
factor in the progression of HIV infection to full blown AIDS (Wallace & Watson, 1990). 
Both psychological and physical stress have been shown to significantly decrease immune 
competency (Lysle et al. , 1988), specifically, studies indicate that stress induces a robust 
suppression of lymphocyte function. Such suppression of lymphocyte function can be 
demonstrated by decreased levels of circulating antibodies (Solomon, 1969), decreased 
reactivity of lymphocytes to mitogen (Keller et al, 1981) or specific antigenic stimulation 
(Jasod and McKenzie, 1976), and increased susceptibility to tumor challenge (Lewis et al ., 
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1984). This increased susceptibility co tumor fo rmation has been linked to suppressed 
function in NK and NK-like cells due to stress. In support of such a connection, there have 
been several studies in animals indicating that stress can have a prominent 
immunosuppressive effect on NK cell fu nction (Lysle et al., 1988; Lewis et al . , 1984). 
Experimental! y , several types of stressors including physical (shock or drugs such as 
morphine) (Cunnick et al., 1988; Fecho et al ., 1991), psychological (conditioned fear) (Lysle 
et al . , 1990) have been used to examine the physiological effects of stress. In Lewis rats, 
electric foot shock (unconditioned stimulus) and conditioned fear/anxiety decrease the 
proliferation of lymphocytes when stimulated by mitogens (Lysle et al . , 1987), decreases 
natural killer cell activity (Lysle et al., 1988), and increases susceptibility to tumor challenge 
(Lewis et al., 1984). A contributing factor to these stress induced decreases in functional 
NK activity are the decreased production of both IFN--y and IL-2 , both of which serve as 
robust activators of cytolytic function (Abbas et al., 1993; Trinchieri et al., 1984). 
Natural killer cell activity is essen tial to protect the body from tumor or viral ly 
transformed cells. ·Stress can decrease NK cell function and the production of activators of 
cytolytic activity resulting in viral infection or development of tumors. During a time of 
stress, enhancement of immune function could serve as a key factor influencing the 
likelihood of illness. Use of immunomodulators/immunostimulators during times of stress 
could greatly reduce illness or disease severity if such immunomodulators could abrogate the 
effects of the stressor, and thereby reinstate normal immune function . 
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The hypothesis of this study is that administration of a crude extract of the bitter melon 
can reduce stress induced suppression of immune function. 
22 
MATERIALS AND METHODS 
Media and Reagents 
The two types of culture medium used were RPMI-1640 culture media supplemented 
with L-glutamine (50 mM), gentamicin (50 µg/ ml) and Hepes buffer (200 mM) (all from 
Gibco Lab, Grand Island , NY), henceforth called supplemented media. Supplemented media 
prepared with 10% Fetal Bovine Serum (FBS) (JHR Biosciences, Lenexa KS) is referred to 
as complete media. All BMP treatments were diluted in Hanks balanced salt solution 
supplemented with Hepes buffer (200 mM) and gentamicin (50 µg/ ml) (all Gibco Lab, Grand 
Island, NY). For use in the mitogen stimulation assay , mitogens concanavlin A (Con A) and 
lipopolysaccharide (LPS) derived from Escherichia coli were purchased from Sigma 
Chemical (St. Louis, MO) and phytohemagglutinin (PHA) was purchased from Burroughs 
Wellcome (England). 3H-thymidine (specific activity 6. 7 Ci/mmol) and 51 Chromium (specific 
activity 419.99 MCi/ mg51 Cr, Dupont-New England Nuclear, Wilmington, DE) were used 
as described in the methods portion. Heparin 100 units/ ml (ELKINS SINN Inc. , Cherry 
Hill, NJ) was diluted in 0 .9 %NaCl solution for use in collection of blood samples. 
Phosphate-buffered saline (PBS) was prepared with NaCl (137 mM) , Na2HP04 (6 mM) , and 
KH2P04 (1.5 mM) , pH 7.2, and sterilized by filtration through a 0.22 µm pore filter. 
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Cell Lines 
The tumor cell line, Y AC-1, a murine lymphoma line was originally obtained from the 
American Type Culture Collection (ATCC) Rockville, MD. The cell line was propagated 
in complete medium. The cells were maintained in log phase at 37'C in a humidified C02 
incubator (5%C02, 95 % air). 
Animals 
For preliminary experiments, female Balb/c scrub mice were obtained from Iowa State 
University Laboratory Animal Resources. Mice were housed 2-4 per cage and they received 
both food and water ad/ibitum. For subsequent experiments, male inbred rats of the Lewis 
strain, 52-58 days of age and 200-240 grams, were obtained from Harlan Sprague Dawley 
Laboratories (Madison, WI). The rats were housed individually for 2-3 weeks at the ISU 
Animal Care Facility in a colony room on a 12-h reverse light-dark cycle maintained through 
artificial illumination. The rats received both food and water adlibitum throughout the 
experiment. Animals were handled every other day for two weeks prior to the injection day, 
during their dark cycle, to acclimate the animals to the handling procedures and the new 
environment. The handling procedures included a simulation of the intraperitoneal (ip) 
injection procedure. 
Bitter Melon Extract Preparation 
The crude bitter melon protein extract (BMP) was prepared as previously described 
(fakemoto, 1982). Briefly, 50 pounds of bitter melon fruit , obtained from California, were 
chopped then homogenized in 10 mM Tris-HCI buffer (pH 6. 7) with 1 mM MgC12, filtered 
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through cheese cloth, then centrifuged at 9,000 x G (Sorvall GSA) for 20 min. The resulting 
supernatant was precipitated with 50% saturated ammonium sulfate (Fisher Chemical, Fair 
Lawn, NJ). The precipitated protein was collected via centrifugation and the pellet was 
resuspended in PBS and dialyzed (Fisher Chemical, spectra/por 3, 45mm wide) against PBS 
overnight to remove residual ammonium sulfate. All procedures for BMP preparation were 
conducted at 4°C. This crude aqueous extract was stored at -80°C in 1.5 ml aliquots and 
used as the source of crude bitter melon preparation. This extract is stable for up to 1.5 
years at -70°C and was tested for activity in mice prior to, and periodically throughout, the 
rat study (data not shown). 
The crude protein content was determined using the colormetric Bio-rad Protein Assay 
and was determined to be 9.437 mg/ml using IgG as a standard. Prior to injection treatment, 
the crude bitter melon protein extract was thawed and centrifuged at 3000 rpm for 5 minutes. 
The supernatant was filter-sterilized using a 0.2 micron filter, and diluted in supplemented 
HBSS to 50 µgl ml. The denatured control samples were heated at a full boil for IO minutes 
then filtered and diluted like the non-denatured samples. A total volume of 2 ml was 
injected ip four days prior to sacrifice. Animals in the control group were given 2ml ip of 
the diluent (HBSS). Injections of bitter melon protein (BMP) ranging from 30-3000 µglml 
as indicated in the results, denatured protein, BMP or HESS were given 4 days prior to the 
animal sacrifice. 
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Preparation and Enumeration of Effector Cells 
Peritoneal exudate cells (PEC) were obtained from BMP-treated rats and control rats via 
peritoneal lavage with 50 ml of supplemented HBSS. The lavage fluid was centrifuged at 
1500 rpm for 10 minutes, and the cell pellet was resuspended in 4 ml complete media and 
counted using a Celltrak 2 (NOVA Biomedical, Waltham, MA). The cells were diluted to 
2.5 x 106 cells/ ml. 
Spleens were ground between the frosted ends of glass slides, in 8 ml complete media, 
in order to obtain a single cell suspension. The cell suspension was allowed to settle for 5 
minutes and the supernatant (containing the single cell suspension) was removed. The cells 
were enumerated as above and diluted to 5.0 x 106 cells/ml. 
Differential leukocyte counts were performed by a certified Medical Technologist 
(ASCP) on cytospin prepared slides fixed in methanol and stained with Wright-Geimsa stain 
(Fisher Chemical , Fair Lawn, NJ). Slides were prepared by adding 35 µ1 or 55 µl spleen 
or PEC single cell suspension (above) to 160 µ1 of 1 % BSA in PBS in the cytocentrifuge 
sample carrier. Slides were centrifuged at 700 rpm for 5 minutes , then immediately fixed 
and stained and at least 100 cells were counted. 
Assay for Tumor Cytotoxicity 
Tumor cytotoxicity was measured using a 51Cr-release assay (Tadayoshi, 1981), utilizing 
the NK sensitive tumor cell line, YAC- 1 (murine T-cell lymphoma) as tumor target cells. 
Briefly, the effectors (spleen or PEC) were prepared as above and plated in triplicate at 10, 
5, 2 .5 , and 1.25 x 105 cells/well to obtain effector to target ratios of 100:1 , 50:1, 25:1, and 
26 
12.5: 1 for the spleen, and plated at 5, 2.5, 1.25 x IOS and 0.75 cells/well to obtain effector 
to target ratios of 50:1, 25:1 , 12.5:1 and 6.25:1 for the PEC samples. All samples were 
plated in a 96-well, flat-bottom, microtiter plate and incubated for 4.5 hours at 37°C in a 
humidified C02 incubator. Tumor target cells were harvested and washed once with 10 ml 
of media. Tumor cells (7.0 x 106cells) were resuspended in 200-300 µl complete media and 
incubated for 70 minutes with 200 µCi sodium [51Cr]-chromate (Dupont-New England 
Nuclear, Boston, MA). The cells were washed in 30 ml complete media , and incubated for 
another 30 minutes in 5 ml complete media to reduce spontaneous leakage of 5 1Cr during the 
assay. After the 30 minutes incubation, the cells were washed twice more in 14 ml media 
to remove remaining extracellular chromium, then counted for viability using trypan blue 
exclusion. The tumor cells (targets) were resuspended at 2 x 105 cells/ml of complete 
media, and 50 ul of this suspension was added to the wells after the samples had been 
plated. 
Control wells were plated using complete media and target cells to determine 
spontaneous release and maximum release. The maximum release was determined by Iysing 
all of the targets with 10% trichloroacetic acid just prior to harvesting the samples. Next, 
the plates were centrifuged at 500 rpm for 5 minutes , 100 µl of the supernatant was 
removed, and counts per minute were determined on a gamma counter (Gamma Trac 1191: 
TMAnalytic, INC, IL). Cytotoxic activity is represented as lytic units. Lytic units are 
defined in terms of the number (lx107) of effector cells required to give 20 % specific lyisis 
of 1 x 1()4 target cells [ (LU) 20%/107 effectors]. Data from all E:T ratios are used to 
calculate the LU. 
Flow Cytometry 
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Flow cytometric analysis of cell surface proteins were performed on both the spleen and 
PEC cell suspensions using flourescently tagged monoclonal antibodies and an EPICS 
PROFILE-1 to perform the analysis. Anti-CD8alpha (OX-8) biotinylated for conjugation to 
strepavidin-cychrome, anti-CD4 antibody conjugated to fluorescein iso-thiocyanate (FITC) 
and anti-CD3 conjugated to phycoerythrin (PE) were used for three color analysis (all from 
PharMingen, San Diego, Ca). Additionally, mouse anti-rat NKR-Pl antibody, FITC 
conjugated (Harlan Laboratories, Madison, Wis) was used for one color cell staining. 
Isotypic controls used were FITC or Biotin conjugated mouse IgG 1 k or IgG2k antibodies 
(PharMingen, San Diego, Ca) to determine nonspecific binding. Briefly, 5x 1 OS cells/tube 
in 0.2 ml phosphate-buffered saline (PBS) containing 0. 1 % sodium azide were incubated with 
previously titered optimal concentrations of CDS and CD3 or NKRI-P murine mAbs or 
isotypic control antibodies for 20 minutes at 4°C, in the dark. The cells were washed once 
with PBS/azide, the red blood cells were lysed using a lx ammonium chloride lysing 
solution, and the cells were washed two more times. At this point the second-step 
flourochrome (i .e., strepavidin-cychrome) was added to the samples for 20 minutes at 4°C, 
in the dark. All samples were washed twice more, as above, and re-suspended in a 1 % 
paraforrnaldehyde solution for analysis at the ISU Flow Cytometry facility . Analysis was 
performed by gating on the lymphocyte population as determined by forward light scatter vs 
side scatter. In order to determine phenotypic cell type, gates were set for each experiment, 
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based on isotypic controls, to optimize separation of the fluorescent signals and greater than 
10,000 events were counted. 
Mitoeen Stimulation Assay 
A mitogenesis assay was performed on splenic leukocytes (Lysle et al., 1988). In order 
to determine lymphocyte proliferation, con A (3.0 µg/ml) and PHA (10.0 µg/ml) were used 
as T lymphocyte mitogens and LPS (5.0 µg/ml) as a B lymphocyte mitogen. The whole 
spleen single cell suspensions were diluted in complete media to 5x106 leukocytes/ml. The 
spleen cultures were pulsed with lµCi 3H-thymidine (specific activity 6. 7 Ci/mmol; Dupont-
New EnglandNuclear) in 50 µl of supplemented RPMI-1640 during the last 5 hours of a 48-
hour incubation at 37°C in a C02 incubator. The cultures were harvested onto glass fiber 
filter paper using a Skatron Cell Harvester (Skatron Inc., AS, Norway) and the incorporation 
of 3H-thymidine was measured with a liquid scintillation counter (Wallac Inc., Gaithersburg, 
MD). Data were expressed as counts per minute (cpm) ±SEM. 
Plasma Corticosterone Assay 
A sample of heparinized blood obtained via heart puncture was centrifuged at 3000 rpm 
for 25 minutes, and 1 ml of plasma was removed and frozen at -80°C. Plasma corticosterone 
was determined using a competitive protein binding assay as previously described by Murphy 
(1967) . Breifly, 400 µ1 of ethanol (100%) was added to 200 µl of each plasma sample in 
a microfuge tube, vortexed and centrifuged at 6000 rpm for 3 minutes . The supernate 
suspension, 100 or 200 µl , was transferred to polystyrene tubes, in duplicate and evaporated 
under air in a 45°C water bath. For samples from the stress group 100 µl of supernate was 
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used due to high levels of corticosterone. Additional! y, a pooled high sample was run at the 
beginning, and end, of all samples to monitor assay variance. Corticosterone (Sigma), 
ranging from 0 to 32 µg/dl was prepared in 100% ethanol as a standard curve. The 
standards were pipeted directly into polystyrene tubes and evapoated to dryness under air in 
a 45° C water bath. After drying, 1 ml of a CBG isotope solution (0.08 % 3H corticosterone, 
2% human salvage plasma, in 100% ethanol) is added to each tube of sample and standard. 
The tubes are vortexed vigorously and incubated in a 45° C water bath for 10 minutes. The 
tubes are subsequently cooled below 5°C in an ice-water bath for 20-50 minutes. Florisil (40 
mg) is added to each tube, the tubes are shaken on a horizontal shaker for 2 minutes at a 
speed that just lifts the flourisil into suspension, and the tubes are placed in the ice-water 
bath for 10 minutes to allow the flourisil to settle. The sample or standard supernatant (0.5 
ml) is transferred to a scintillation vial with 3 ml of scintillation fluid. To determine total 
counts 0.5 ml of CBG-isotope solution is added to 3 ml of scintillation fluid. Radioactivity 
is determined by counting for 2.5 minutes on a Beta-scintillation counter (LKB Rackbeta). 
Data reduction of the standard curve and interpolation of sample values using a Lotus 
program was performed in order to calculate corticosterone content of the samples. This 
assay is sensitive to 0.2 µgldl. 
Shock Appparatus 
Eight identical rodent chambers (BRS/LVE Inc. , Laurel, MD, small animal chamber, 
Model RTC-020), measuring 25 x 30 x 28 cm, served as the shock apparatuses. The 
chambers have clear Plexiglas side walls, sheet-metal top and end walls, and a grid floor 
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consisting of bars 0 .24 cm in diameter, spaced 1.4 cm apart. The boxes are connected by 
timer circutry to the output of a shock generator and scrambler (BRS/L VE Models 903 and 
SC922) to provide a 5.0-second, 1.6-mA, foot-shock that was scrambled throughout the 
floor bars. The chambers were individually housed in identical sound-attenuating cubicles, 
36 x 56 x 42 cm (BRS/LVE, Model SEC-002). A 100-W, 120-V bulb, recessed in the wall 
of the cubicle, was operated at 85-V, AC, to provide diffuse illumination of the chamber. 
An ambient sound level of 72dB was provided by operating the cubicle's ventilating fan at 
57 V, AC. 
Stress Paradigm 
For experiments in which stress was a factor, half of each injection group was randomly 
assigned to receive shock or serve as home cage (control) animals. The stress subjects were 
presented with 16 shocks, randomly delivered throughout a single 64-min session. The 
session began approximately 1-3 hours into the dark phase of the day-night cycle. The 
shocks were delivered every 2-6 minutes, with the time between shocks averaging 4 minutes. 
There was no discreet stimulus accompanying the shock. Home cage control subjects were 
handled and transported in a manner identical to the stress subjects, but were not placed in 
the shock aparatus. 
Twenty minutes after the last shock, the subject was rapidly sacrificed by cervical 
dislocation. The control subjects were transported from their home cages to the chamber 
room and sacrificed in the same mannner and at approximately the same time (one animal 
from each injection group in no-shock treatment then one animal from each injection group 
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in the shock treatment) as the experimental subjects. Blood was collected via heart puncture 
into 5-ml heparinized syringes, the peritoneum was washed twice with a total of 50 ml of 
supplemented HBSS and the liquid from each animal was removed and pooled in a 50 ml 
polystyrene centrifuge tube, the spleen was removed and placed in a 15-ml polypropylene 
centrifuge tube containing supplemented media. All samples were transported to the tissue 
culture laboratory for preparation. 
Statistical Treatment of Data 
A computerized program for analysis of variance (Statistix, NH Analytical Software) was 
used to determine differences among experimental and control groups. A one by six 
ANOV A compared differences among groups for the dose response curve study. A two x 
three ANOV A was used with two levels of stress (shock treatment or home cage) and three 
levels of drug (bittermelon-BMP, denatured bittermelon-DBMP or HBSS (saline) injection) 
for the experimental paradigm using stress. 
The significance level for all analysis was set at a probability less than or equal to 0.05 . 
All data are shown as mean + SEM. All significant main effects and interactions were 
further examined using orthogonal contrasts and t-tests. Additionally the hypothesis led 
investigators to examine differences between stressed BMP group and non-stressed controls. 
Preliminary Experiments 
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RESULTS 
Stimulation of Tumor Cytolytic Activity 
To initially determine whether the crude BMP contained the immunostimulatory 
proteins, the extract was tested in mice. Mice were injected ip with 0, 4, 8, 16 or 32 
µg of protein, ip, from the BMP four days prior to sacrifice. Peritoneal exudate cells 
were harvested, enumerated and assayed for tumor cytotoxicity. It was determined that 
the administration of BMP produced in our laboratory increased tumor cytotoxicity of 
mouse PEC cells at a dose equivalent to previous reports (8 µg/ml) (data not shown). 
Upon determination that the extract contained immunostimulatory properties in 
mice, investigators proceeded to determine if an increase in cytolytic activity could be 
demonstrated in rats, and what dose of protein would yield the highest lytic activity 
against NK sensitive targets . Intraperitoneal injections of 0-1000 µg of BMP were tested. 
Heat denatured protein (100-HD µg) and hanks balanced salt solution (HBSS-0 µg 
protein) injection were used to as control treatments. Both peritoneal and spleen 
leukocytes were assayed for anti-tumor activity and the results are shown in Figures 1 
and 2, respectively. 
In PEC and spleen cytotoxicity data there was a main effect of treatment (F's 
(4,23)=6.44 and (4,24)=5.27 respectively, p 's< .005). While the PEC from all groups 
receiving either a bitter melon injection had significantly (p <. 05) higher tumor cytotoxic 
activity than the HBSS control group. The PEC from the group receiving 100 µg of 
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FIGURE 1. Tumor cytotoxicity of rat peritoneal exudate cells in response to various doses of 
bitter melon protein extract (BMP) or heat denatured bitter melon extract. The BMP 
was diluted in hanks balanced salt solution and all injections were given in 2 ml 
delivered i.p. The group which received 100 µg BMP had significantly higher levels 
of tumor cytolytic activity (lytic units) against Y AC-1 tumor targets in comparison to 
both control groups: heat denatured protein (100 µg-HD) and 0 µg protein (HBSS) 
(p < .05). Results are represented the mean (± SEM) for the designated group 
(n=S). 
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FIGURE 2. Tumor cytotoxicity of rat spleen leukocytes in response to various doses of bitter 
melon extract or heat denatured bitter melon protein extract. The BMP was diluted in 
hanks balanced salt solution and all injections were given in 2 ml delivered i. p. The 
group which received 500 µg bitter melon extract had significantly higher levels of 
tumor cytolytic activity against Y AC-1 tumor targets in comparison to both control 
groups: heat denatured protein (HD) and 0 µg protein (HBSS) (p < .05) . Each group 
represents the mean (± SE) for the designated group (n =5). 
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protein had significantly (p < .0005) higher cytotoxic activity than all of the other groups 
that received a bitter melon injections. The 100 µg heat denatured control did have 
elevated cytolytic activity in comparison to the HBSS, but this was not significant. 
In contrast, results of the tumor cytotoxicity of splenic leukocytes (Figure 2) show 
animals which received 500 µg protein had significantly (p < .005) higher anti-tumor 
activity than animals in the other bitter melon injection groups; while all animals 
receiving bitter melon injection were also shown the have significantly (p < .05) elevated 
cytotoxicity levels in comparison to the HBSS control group. There was no significant 
difference in cytotoxicity between the denatured and HBSS control groups. 
Doses of BMP above 1000 µg protein and below 100 µg protein were also tested 
for stimulation of cytotoxicity (data not shown). The doses of BMP > 1000 µg induced 
weight loss in animals indicating illness or possible toxic effects. The data obtained from 
PEC of animals receiving such doses exhibited lytic units similar to the HBSS control 
groups confirming detrimental effects of such high doses. As our interest for this study 
was to examine modulation of peritoneal exudate cells, 100 µg bitter melon protein was 
chosen as our experimental dose for further studies. 
Combined Effects of Stress and Bitter Melon 
An experiment was designed to examine the effects of stress on the tumor 
cytolytic activity of PEC as well as the ability of BMP administration to block this 
modulation of tumor cytolytic activity. In this experiment , bitter melon was administered 
as three levels of drug (100 µg protein (BMP), 100 µg denatured protein (HD) , or O µg 
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protein (HBSS)). On the experiment day , half of the animals from each injection group 
were stressed by presentations of mild electric foot-shock. Plasma, spleen and peri toneal 
exudate cells were collected and assayed in order to determine if the animals experienced 
stress and determine modulation of plasma corticosterone levels, splenic mitogen 
response, leukocyte cytolytic function, cell numbers , and phenotypic markers as a result 
of the drug and/or stress treatments. 
Corticosterone 
As an indicator of stress, plasma corticosterone was measured and the results are 
shown in Figure 3. ANOVA indicates that plasma corticosterone levels in the shock 
group are significantly (p < .001) higher than the levels in the no-shock (home cage) 
animals, indicating that the animals were stressed. There was no significant main effect 
of drug dose on corticosterone level or interactions of stress and drug. These results 
suggest that BMP treatment does not alter the animals response to stress. There was a 
main effect of replication and a main effect of replication and stress in corticosterone 
levels found in the plasma, due to the second replication having proportionally lower 
levels of corticosterone than the first replication. However, the directions of change due 
to stress treatment were similar in both replications. 
Lymphocyte Prolif era ti on 
Spleen lymphocyte proliferation responses to mitogens were performed to 
determine immune suppression of this parameter which has previously been reported to 
be decreased due to stress. There was no significant effect of stress, drug or an 
interaction of stress and drug on the proliferation of lymphocytes in response to T cell 
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FIGURE 3. Concentration of corticosterone in plasma from stressed (electric foot shock) 
and non-stressed (home cage control) subjects. Stressor consisted of 16 random 
electric foot shocks, 5 second duration , 1.6 mAmps,in a 64 minute shock session. 
Corticosterone levels were significantly higher in the stress groups in comparison to 
the home cage controls (p< .001) .There was not a significant difference in 
corticosterone levels between the drug - bitter melon (n = 6), denatured bitter melon 
(n=6), or hanks balanced salt solution (n=6) treatment groups. Each bar representes 
the mean (±SE) for the designated group. 
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mitogens Con A and PHA or the B cell mitogen LPS (data not shown) . The mean CPM 
in response to con A, PHA, or LPS was 2.92 x 105, 1.78 x 104 and 1.83 x 104, 
respectively. 
Assay for Tumor Cytotoxicity 
Cytotoxicity to Y AC-1 cells by PEC and splenocytes was evaluated in rats 
receiving an injection of BMP and/or stress and the results are shown in Figure 4. In 
agreement with preliminary experiments, there was a significant main effect of drug , 
F(2,20) = 122.6, p < .0001 , which was due to a significantly higher killing of tumor cells 
by PEC in the BMP group compared to the two control groups (p < .0001). Additionally, 
stress induced a significant suppression of lytic activity against tumor target cells in the 
PECs, F(l ,20)=20.97, p<0.005. Although no significant interaction was found 
between the bitter melon administration and stress treatment, planned contrasts indicated 
that the LU were significantl y higher in the BMP-stress group than either the HD/No-
shock or HBSS/ No-shock control groups (p's< .0001). 
Cytotoxicity to Y AC-1 cells by splenocytes was evaluated and the results are 
shown in Figure 5. The administration of bitter melon protein did not show a significant 
increase in tumor cytotoxicity in comparison to the control groups. This is not surprising 
because 100 µg protein did not affect splenic tumor cytolytic activity in preliminary 
experiments (see Figure 2). However , there was a significant effect of stress in the 
splenocytes, F(2,22) =6.4 , p < .05 , that resulted in suppression of tumor cytotoxicity in 
comparison to the home cage control animals for all doses. 
There was a significant main effect of replication in both the PEC and the spleen 
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FIGURE 4. Tumor cytotoxicity of peritoneal exudate cells from stressed (electric foot shock) 
and non-stressed (home cage) subjects four days after an i.p. injection of 100 µg 
bitter melon protein extract (BMP; n= 6), 100 µg heat denatured bitter melon (HD; 
n = 6), or 0 µg protein (HBSS; n = 6). Tumor cytotoxicity was significantly (p < .0005) 
suppressed by stress. The groups injected with bitter melon protein had significantly 
greater tumor cytotoxicity than the heat denatured or HBSS groups (p < .0001). Each 
bar represents mean (±SE) for the designated group. 
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FIGURE 5. Mean (±SE) tumor cytotoxicity by splenocytes in stressed (electric foot shock) 
and non-stressed (home cage) subjects four days after an i.p. injection of 100 µg 
bitter melon protein (BMP; n = 4) , 100 µg heat denatured bitter melon protein (HD; 
n=6), or 0 µg protein (HBSS; n=6). Tumor cytotoxicity was significantly 
suppressed due to stress (p< .05) . The groups injected with BMP did not have 
significantly higher tumor cytotoxicity in comparison to the HD and HBSS control 
groups. 
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that interacted with dose and stress. This was due to the second replication having 
proportionally lower lytic units than the first replication. However, the direction of 
change in both replications was similar. 
Leukocyte Enumeration and Identification 
In order to better understand the mechanisms of this immunostimulatory agent, 
the cells were enumerated and identified by Wright-Giemsa staining. As shown in Figure 
6 , the PECs displayed a significant increase in the number of cells recovered in the 
peritoneal wash as a result of administration of the BMP when compared to either the 
heat denatured or HBSS control , F(2 ,21) = 67.87, p< .0001. Recovery of PEC in the 
BMP treated group, regardless of stress treatment, was in excess of 8.0 x 107 cells, but 
both the denatured and HBSS groups cell numbers were below 3.0 x 107 cells. There was 
no main effect of stress on number of leukocytes recovered. The spleen leukocyte counts 
did not vary significantly as a result of either the drug treatment or the stress treatment 
(data not shown). 
To identify the cell types resident in the peritoneum and determine if the treatments 
favored an increase of one particular type of cell , leukocyte differential cell counts were 
performed (see Table 1). The major type of cell found in the peritoneum regardless of 
shock or drug treatment was macrophages. The majority of cells found in the spleen was 
lymphocytes, and there was no main effect of drug or shock treatment on cell type. 
Flow Cytometry 
In order to determine if the increased lytic activity was due to an increase in a 
particular cell linage or merely a global increase in activity, cell surface staining and 
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FIGURE 6. Mean (+SE) of number of leukocytes recovered from peritoneal lavage 4 days 
after ip injection of 100 µg bitter melon protein (BMP; n=4), lOOµg heat denatured 
bitter melon protein (HD; n = 6) or 0 µg protein (HBSS; n = 6). All injections were 2 
ml, ip. The groups which received BMP had significantly (p < .0001) higher leukocyte 
numbers than the HD or HBSS control groups. There was no significant difference 
due to stress. 
Table 1. Lymphocyte differential cell counts of spleen and peritoneal exudate cells from stressed (electric foot shock) 
and non- stressed (home cage) four days after ip injection of bitter melon protein (BMP), denatured bitter 
melon protein (HD)or hanks balanced salt solution (HBSS). There was no significant difference in cell 
counts due to stress or drug. Greater than 100 cells were counted (n=6). 
basophil neutrophil monocyte eosinophil lymphocyte macrophage 
Spleen 
No shock 0% 
BMP 1% 0% 1% 0% 98% 0% 
Den at. 0% 0% 2% 0% 98% 0% 
HBSS <1% 0% 2% 97% 0% 
Shock 
BMP 0% 0% 1% 0% 99% 0% 
Den at. 0% 0% 1% 0% 99% 0% 
HBSS 0% 0% 1% 0% 99% 0% 
PEC 
No shock 
BMP 0% <1% 72% 7% 20% 0% 
Denat. 0% 0% 73% 12% 16% <1% 
HBSS 0% 1% 75% 12% 10% <2% 
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FIGURE 7. Percent CD3+ and CD8a+ leukocytes recovered from peritoneal lavage of rats 
4 days after i.p. injection with 100 µg bitter melon protein (BMP; n=4), IOOµg heat 
denatured bitter melon protein (HD; n=6) or 0 µg protein (HBSS; n=6). Animals 
that received bitter melon injections had a significantly (p < .0001) higher percentage 
of double positive cells than either the HD or HBSS control groups. There was no 
significant difference due to stress. Each bar represents mean (+SE) for the 
designated group. 
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flow cytometric analysis were performed. The cell phenotype was evaluated in both the 
spleen and peritoneal exudate leukocytes using antibodies to rat CD3 (f cell), CD8a (Tc 
or NK), or NKR-Pl (NK cell). Figure 7 shows the peritoneal exudate cells of the BMP 
treated animals contained a significantly higher proportion of CD3+cn8+ double positive 
lymphocytes than the other two treatment groups, F(2,15)=50.23, p<.0001. Figure 8 
shows that the BMP administration also significantly increased the number of NK cells 
recovered from the peritoneum , F(2,19)= 16.25, p< .001. There was no main effect or 
any interaction between drug and stress on number of NKR-Pl positive cells in the PEC. 
There was no main effect of stress or any interaction between drug and stress on the 
percentage of CD3+co8+ or NKR-P 1 + cells in the PEC. 
Splenocytes were also analyzed fo r any changes in phenotypic cell type, no 
significant changes in population occurred as a resul t of drug, stress or any interaction 
between stress and drug. 
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FIGURE 8. Percent positive NKRl-P leukocytes recovered from peritoneal lavage of rats 4 
days after i.p. injection with 100 µg bitter melon protein (BMP), lOOµg heat 
denatured bitter melon protein (HD) or 0 µg protein (HBSS). Animals receiving 
bitter melon injections had a significantly (p < .05) higher percentage of positive cells 
than either the HD or HBSS control groups. Our data indicates there are no positive 
cells in the stress-HD or stress-HESS . There was no significant difference due to 
stress. Each bar represents mean (±SE) for the designated group {n =3). 
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DISCUSSION 
Cellular immunity is part of the bodys' primary defense against viral infection and 
tumor formation. A defect or suppression in this critical first line of defense would leave 
an individual more susceptible to disease. New cancer therapies consist of the 
administration of biological ly active compounds, such as JL-2 or one of the IFNs, to 
stimulate anti-tumor activity in patients who are more susceptible to tumor formation . 
Previous studies have indicated that the Chinese bitter melon contains naturally occurring 
immunostimulatory agents (Cunnick, et al ., 1990). The bitter melon has been shown to 
have both anti-viral effects (Lee-Huang et al., 1990) and an ti-tumor effects (Cunnick, et 
al., 1990). Researchers have also indicated that stress induces a robust suppression of 
immune function resulting in decreased anti-tumor activity (Lysle et al., 1988) . The 
administration of bitter melon agen ts may lessen stress induced suppression of tumor 
cytotoxic activity . 
Preliminary experiments have demonstrated that ip injection of 100 µg of bitter 
melon protein extract stimulates the killing of tumor targets by rat peritoneal exudate cells 
in a short-term cytotoxicity assay. This same type of killing was demonstrated in spleen 
leukocytes , though a dose of 500 µg protein was required to detect a significant increase 
in tumor cell lysis (Figures I and 2). T he difference in dose required to stimulate anti-
tumor activity in the PEC and the spleen may reflect the fact that a higher dose causes 
activation sooner in the peritoneum, whereupon the cells then migrate to the spleen. 
Alternatively, the bitter melon protein, at higher doses, might circulate to the spleen 
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through the blood , and activate splenocytes directly. Although the heat denatured 
protein does increase the lytic activity of the effector cells, this increase was minimal 
when compared to the substantial increase in lytic activity seen in the groups that 
received the native BMP injections. Thus, the use of a HBSS (0 µg protein) and a heat 
denatured protein control demonstrates that only a minor part of immunostimulation by 
BMP could be attributed to a nonspecific stimulatory effect of injecting protein in a 
substantial volume into the peritoneum. 
The second experiment used a common paradigm of unpredictable mild electric 
foot shock (Lysle and Lyte, 1987; Cunnick et al . , 1988). To determine if administration 
of the BMP could reduce stress induced suppression of tumor cytotoxic native BMP, heat 
denatured bitter melon and HBSS were administered in combination with stress (electric 
foot shock) or no-stress (home cage) treatments. This paradigm was stressful to the 
animals as evidenced by the significant increase in corticosterone. Additionally, 
presentations of shock resulted in suppression of anti-tumor activity in both the spleen 
and peritoneal exudate cell s. Administration of BMP induced a substantial increase in 
tumor cytolytic activity in the PEC but not the spleen (Figures 1 and 2). Although the 
tumor cytotoxic activity of PEC was suppressed by stress the level of cytotoxicity in 
animals receiving bitter melon and a stressor had significantly higher anti-tumor activity 
than did the no-stress animals in ei ther of the control groups. Interestingly, suppression 
of lytic activity due to stress still occurs in the bitter melon group suggesting that 
administration of bitter melon does not affect the mechanism of stress induced 
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suppression, but rather is activating the immune system directly. It could be proposed that 
injection of a higher dose of BMP, as indicated in Figure 2, would result in similar 
activation of spontaneous splenic tumor cytotoxicity . 
No enhancement was seen in splenic mitogen responsiveness due to injection of 
BMP. Additionally , there was not the expected suppression of splenic mitogen 
responsiveness due to stress as previously reported. The investigators theorize that the 
anomaly (lack of stress induced suppression) in the mitogen response is due to the change 
in the time of sacrifice after the shock session from 0-20 minutes to 20-50 minutes post-
stress. Previous investigators have seen that stress induced suppression of mitogen 
responsiveness recovers in less than 24 hours (Lysle and Lyte, 1987), while the present 
study suggests a more rapid recovery. Indeed preliminary experiments demonstrated 
suppression of mitogen responsiveness when the rats were sacrificed 0-20 minutes post-
stress (data not shown). However , stress induced suppression of NK activity was 
marginal at that time. The sacrifice times were shifted in order to optimize NK 
suppression, but suppression of mitogen responsiveness was lost, reflecting the 
possibility of different mechanisms mediating stress induced immune suppression. 
Interestingly , most reports of NK suppression examine animals at 24 hours post-stress 
(Shavit et al . , 1984). Thus, a greater suppression of cytotoxicity may be seen if the 
sacrifice time was shifted beyond 50 minutes post-stress. 
In the past, all spontaneous cytotoxic activity was attributed to natural killer cells 
because the standard assay used to detect tumor cytotoxicity (5 1chromium release assay) is 
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a functional assay and can not distinguish spontaneous killing between cell types. 
Additionally , the cell lines used as tumor targets are known as NK sensitive targets 
(Deju, 1975), which fosters the erroneous notion that only NK cells can kill such tumor 
target cells. Recently, a number of different cell types have been shown to possess the 
ability to kill in a spontaneous, MHC-unrestricted manner (Cesano et al., 1993; Matthew 
et al. , 1993; Okumura et al ., 1995). It is reasonable to think that it is possible to 
stimulate such anti-tumor activity in a manner similar to that of NK cells. Activation of 
tumoricidal cells is clearly advantageous in any situation; however, during a time of 
stress when immune function is suppressed, augmentation of anti-tumor activity would be 
particularly significant. We have shown that the Chinese bitter melon possesses 
substantial immunostimulatory properties in both splenic and peri toneal lymphocytes and 
that suppression of PEC activity can be demonstrated as a result of stress. Plasma 
corticosterone levels in all groups indicate that the animals that received shock were 
stressed. For our purposes, corticosterone is measured as an indicator of stress, the data 
do not determine i f the suppression is a direct effect of corticosterone or some other 
hormone acting on the cells. 
Administration of bitter melon caused a large increase in cell numbers in the 
peritoneum, regardless of stress treatment. Cell differentials indicate that the number of 
lymphocytes remains relatively constant across all groups (Table 1). This finding leads 
us to question whether activation of lytic activity was a result of increased activational 
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state of all cell types or if certain key cell types were preferentially undergoing drug 
induced proliferation (Figures 6 , 7 and 8). 
Through flow cytometric analysis it was demonstrated that treatment with bitter 
melon protein enhances the percentage of cells in at least two populations found in the 
peritoneum. Natural killer cells were seen to increase in numbers by approximately 10% 
(Figure 8), as did a CD3+CD8+ cell population (Figure 7), while the percentage of 
lymphocytes remained the same across all groups (Table 1). These findings suggest that 
it is a shift in lymphocyte cell type or maturational level and not an influx of lymphocytes 
that causes the increased anti-tumor activity. The results do not indicate if the increased 
anti-tumor activity was a direct result of the increased double positive population, 
increase in natural killer cell population, a combination of the two or some other factor. 
It is possible that the administration of the bitter melon causes a more systemic 
activation of immune function which is causing the release of cytokines that may 
stimulate tumor cell immunity. Many types of cells are capable of NK-like killing, 
particularly in response to cytokines. It is possible that administration of the bitter melon 
activates macrophages which secrete IFN-a, -{3 and/or TNF-a, known activators of NK-
like killing in CD3+CD8+ cells. 
In summary, the results indicate administration of bitter melon protein induces 
increased cell numbers and activation of tumor cytotoxic peritoneal exudate cells in rats, 
and that this enhancement persists in the face of stress. It has been shown that this 
activity may not be entirely due to natural killer cell activity as previously thought but 
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that it may be partially due to activation of CD3+CD8+ cells; a cell line only recently 
identified as having the capacity for MHC-unrestricted kill ing. 
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